Cairo - Mubasher: Minapharm Pharmaceuticals registered an annual surge in non-consolidated net profits after tax to EGP 66.56 million during the first nine months (9M) of 2025, versus EGP 17.13 million.
The earnings per share (EPS) dropped to EGP 2.18 as of 30 September 2025 from EGP 9.88 in 9M-24, according to the financial results.
Non-consolidated net sales reached EGP 2.88 billion in 9M-25, reflecting a year-on-year (YoY) rise from EGP 2.17 billion.
Standalone total assets amounted to EGP 11.25 billion in 9M-25, compared with EGP 9.81 billion in the twelve-month period that ended on 31 December 2024.
Financials for Q3-25
During the third quarter (Q3) of 2025, the non-consolidated net profits after tax plummeted to EGP 29.84 million from EGP 114.97 million in Q3-24, whereas the EPS shrank to EGP 2.18 from EGP 9.88.
Minapharm generated standalone net sales of EGP 962.66 million in the July-September 2025 period, which came higher YoY than EGP 863.74 million.
